Delivery Order SPE2D021D0005-SPE2D324F183N
Award Date
8/7/24
Potential Completion Date
8/12/24
Potential Value
$3.3K
Federal Agency
Medical Supply Chain
Awardee
Genentech Usa, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
South San Francisco, CA 94080, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology company that manufactures pharmaceuticals. The contract is for the delivery of 50 mg vials of the drug Activase (alteplase), which is used to treat ischemic stroke. The award has a ceiling value of $3,256.83 and a period of performance through July 26, 2024. Genentech has multiple contract vehicles with the federal government, including a $4.9 billion Federal...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology and pharmaceutical manufacturer. The $872,420.96 firm fixed-price contract is for the provision of various medical supplies and pharmaceuticals, including critical medications such as Tamiflu, Activase, TNKase, and Xofluza, as well as routine medications like clonazepam and diazepam tablets. The contract has an ultimate completion date of June 22,...
Genentech USA, Inc. was awarded a $3,260.76 delivery order against the Defense Logistics Agency Troop Support Medical indefinite-delivery/indefinite-quantity contract to provide 455,688,378 ACTIVASE 50 MG vials with diluent for injection to the Defense Logistics Agency Troop Support. The place of performance will be Genentech's facility located in South San Francisco, California. The delivery order has a period of performance from April 13, 2022 through April 18, 2022 and utilizes firm fixed...
This federal contract award, valued at $263,722.06, was issued by the Medical Supply Chain division of the Department of Defense to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and biologics. The award is a delivery order contract with a firm fixed price pricing type. Genentech provides a range of pharmaceutical products to federal agencies, including antivirals, specialized treatments, and other medications, through a variety of contract vehicles such as a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology and pharmaceutical manufacturer. The $10,739.70 firm fixed-price contract is for the supply of 4568495914 - TNKASE 50 MG KITS, with a completion date of June 12, 2025. The contract is not associated with a set-aside designation. Genentech has established several significant federal contract vehicles, including a $4.9 billion Federal Supply Schedule...
This is a federal contract award to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, by the Defense Logistics Agency (DLA) for the delivery of oseltamivir phosphate, an antiviral medication. The contract award (SPE2DP18D0011|SPE2DP18F6027) has a ceiling value of $95,976.93 and was issued on a firm fixed-price basis as a delivery order, with a final completion date of September 23, 2019. Genentech is an established federal contractor, holding several vehicles with...
This is a delivery order (SPE2DP16D0008|0041) awarded by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals. The $9,862,682.40 firm-fixed-price contract is for the delivery of oseltamivir phosphate, an antiviral medication, to support the federal government's medical supply needs. The contract does not have a set-aside designation. Genentech holds several key contract vehicles with federal...
This is a federal contract award from the Medical Supply Chain of the Department of Defense to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and biologics. The contract is for the delivery of oseltamivir phosphate, an antiviral medication, with a ceiling value of $149,340.18. The contract is a firm-fixed price delivery order placed under an existing vehicle, with an ultimate completion date of September 21, 2017. No set-aside designation was used. Genentech...
The Defense Logistics Agency Troop Support Medical awarded a $116,303.04 delivery order contract to Genentech USA, Inc. for the antiviral medication oseltamivir phosphate. Genentech is a foreign-owned, for-profit manufacturer of pharmaceuticals that has held numerous indefinite delivery contracts and blanket purchase agreements with various federal agencies for critical biologic medicines. This contract does not utilize any set-asides and will be performed at Genentech's facility in South San...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology company. The $93,573.18 firm-fixed-price contract is for the delivery of oseltamivir phosphate, an antiviral medication. The award falls under a larger indefinite delivery contract between Genentech and DLA valued at $27.9 million to supply medical supplies and critical pharmaceuticals for the Department of Defense. No set-aside designation was used....